Last Updated : July 17, 2017
Details
FilesGeneric Name:
Ixazomib
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Takeda Pharmaceutical Company Limited
Brand Name:
Ninlaro
Project Line:
Reimbursement Review
Project Number:
PC0088-000
NOC Status at Filing:
Post NOC
Strength:
4 mg, 3 mg, and 2.3 mg capsules
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
Adult patients with multiple myeloma who have received at least one prior therapy and have high-risk cytogenetics, or have received at least two prior therapies
Sponsor:
Takeda Pharmaceutical Company Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
Clarification:
Please note that the June pERC meeting was conducted over two days. The target for the posting of pERC Initial Recommendation remains as June 29, 2017.
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : July 17, 2017